Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 3/2021

01-04-2021 | COVID-19 | Letter to the Editor

Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis

Authors: Mohamed Abdel-Maboud, Amr Menshawy, Ahmed Elgebaly, Eshak I. Bahbah, Gehad El Ashal, Ahmed Negida

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2021

Login to get access

Excerpt

The COVID-19 pandemic has affected more than 21 million individuals around the world, with over 750,000 deaths. A large body of evidence suggests that COVID-19 is associated with coagulopathy and induced hypercoagulation. Major thromboembolic events were found in postmortem studies of COVID-19 patients [1]. Likewise, a recent study found a possible anti-inflammatory role of heparin prophylaxis lowering the levels of interleukin-6—which play a role in the cytokine storm of severe COVID-19 [2]. …
Appendix
Available only for authorised users
Literature
1.
2.
3.
Lillicrap D (2020) Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost 18:786–787CrossRef
4.
Thachil J (2020) The versatile heparin in COVID-19. J Thromb Haemost 18(5):1020–1022CrossRef
5.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094–1099CrossRef
6.
7.
Gaertner F, Massberg S (2016) Blood coagulation in immunothrombosis—at the frontline of intravascular immunity. In: Seminars in immunology, vol 28. Academic Press, London, pp 561–569
8.
9.
Li JP, Vlodavsky I (2009) Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 102(5):823–828PubMed
Metadata
Title
Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis
Authors
Mohamed Abdel-Maboud
Amr Menshawy
Ahmed Elgebaly
Eshak I. Bahbah
Gehad El Ashal
Ahmed Negida
Publication date
01-04-2021
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02253-x

Other articles of this Issue 3/2021

Journal of Thrombosis and Thrombolysis 3/2021 Go to the issue

Report

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin

Correction

Correction to: The perplexity of catheter-directed thrombolysis for deep venous thrombosis: the approaches play an important role

Letter to the Editor

Direct oral anticoagulants are effective and safe in the treatment of venous thromboembolism and atrial fibrillation in morbidly obese patients

OriginalPaper

COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis

Report

Excessive fibrinolysis detected with thromboelastography in a case of amniotic fluid embolism: fibrinolysis may precede coagulopathy

OriginalPaper

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits